Obicetrapib (CETP inhibitor)

The selective CETP inhibitor lowered Lp(a) by 37 percent (15 nmol/L; 43 percent, 36 nmol/L, at baseline 50 to 150 nmol/L) alongside a 37 percent LDL-C reduction in a pooled analysis of 2,356 phase 3 patients (Nicholls, EHJ 2026). Recommended for EU approval on 24 July 2026 as an LDL-C-lowering therapy; the PREVAIL outcomes trial reports in 2027. Relevant to the many patients below RNA-trial thresholds. See the sister site cetpinhibition.org.